Although these findings support that direct chemical stimulation of the α7nAChRs is effective in attenuating GI inflammation, Snoek et al. (2010) reported that systemic applications of nicotine and two selective α7nAChR agonists AR-R17779 and GSK1345038A have no significant beneficiary effect on disease severity in two mouse models of experimental colitis. Here, CHRNA7 is linked to colitis.